Developer docs
API playgroundTry for free, no card

Search company profiles

Macrocyclics

Full company profile

uuid0025bqf

Namestring
Macrocyclics
Legal namestring
Macrocyclics, Inc.
Company typeenum
Private
Founded yearint
1995
Descriptiontext

Macrocyclics is a Plano, Texas-based contract development and manufacturing organization (CDMO) that designs, synthesizes, and supplies macrocyclic chelating agents used to bind radioactive metal ions for radiopharmaceuticals, MRI contrast agents, and nuclear medicine research applications. Founded in 1995 by Professor A. Dean Sherry as a successor to Magnetic Resonance Solutions (1993), the company operates from a 20,000-square-foot facility equipped with two modular cGMP manufacturing suites, kilo-scale production equipment, and labs licensed for radionuclides used in PET imaging and therapeutic applications. Its core technology is macrocyclic chelation chemistry, with proprietary expertise spanning bifunctional chelators (DOTA, DTPA, NOTA, DOTAGA derivatives), macrocyclic ligands, pre-formed lanthanide complexes (e.g., Lu-DOTA, Gd-DOTA), and the Macropa™ platform for Ac-225 targeted alpha therapy, which is held under exclusive sublicense from Ratio Therapeutics.

The company's revenue model combines a transactional e-commerce catalog of more than 100 chelating agents and related reagents with project-based custom synthesis, bioconjugation, analytical testing, and cGMP manufacturing services quoted directly to enterprise customers. Pricing on catalog items ranges from roughly $62 to over $8,500 per unit, while custom and GMP work is quoted on multi-week lead times (a 10-week minimum for GMP production, with quotations issued within two weeks). Primary customers are pharmaceutical and biotechnology developers of radiopharmaceuticals and nuclear medicine programs, with a secondary segment of academic and molecular imaging research institutions. Marketing is heavily concentrated in industry conferences (SNMMI, WMIC, TRP Summit, ACS) and scientific publications.

Macrocyclics operates as a wholly-owned subsidiary of Orano Med, itself part of French nuclear conglomerate Orano Group, following an October 2011 acquisition that originated from an earlier cGMP contract for Orano Med's Pb-212 clinical program. The relationship with Orano Med underpins capital expansion: the company doubled its footprint in 2019 (Phase II) and completed a further Phase III expansion in June 2025, concurrent with acquiring exclusive Macropa™ commercial rights. Leadership rests with a small, PhD-heavy operations team including CEO Paul Jurek, Senior Chemist Eric Anderson, Production Lead Federico Rojas, and Manager of Business Development Duke Halloran.

Short descriptiontext

Macrocyclics is a Plano, Texas-based CDMO that designs and manufactures macrocyclic chelating agents and cGMP APIs for radiopharmaceutical and nuclear medicine developers worldwide. It serves pharma, biotech, and academic research customers through catalog sales, custom synthesis, bioconjugation, and clinical-stage GMP manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPlano, United States
HQ citystring
Plano
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
macrocyclic chelating agents, radiopharmaceutical manufacturing, cGMP API production, bifunctional chelators, MRI contrast chemistry
Industry2 codes
PRIMARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Industrial Organic Chemicals2860
Product category
Radiopharmaceutical Contract Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Catalog Product Sales
TypeOne Time License
Description

Sale of catalog chelating agents and related compounds through an e-commerce platform. Products include Bifunctional Chelators (BFCs), Macrocyclic Ligands, Magnetic Resonance Reagents, Reactive Intermediates, Fluorescent Probes, Conjugates, and Macropa for Ac-225. Pricing ranges from $62 to over $8,500 per unit depending on product and quantity.

macrocyclics.com
2cGMP Manufacturing for Clinical Trials
TypeOne Time License
Description

Custom GMP production of chelating agents, labeling precursors, and small molecule APIs for clinical investigation. Includes feasibility studies, engineering runs, GMP manufacturing, and final project reports with Statement of Work, raw materials data package, and Certificates of Analysis. 10-week minimum lead time; quoted upon request.

macrocyclics.com
3Custom Organic Synthesis
TypeProfessional Services
Description

Custom synthesis of new linker mechanisms, drug conjugates, imaging precursors, and complex intermediates at scales from multi-milligram to multi-gram and kilogram. Services include modification to chelator/linker, small molecule conjugates, and PET tracer precursors.

macrocyclics.com
4Bioconjugation Services
TypeProfessional Services
Description

Pre-clinical conjugation services for clinical trials, including evaluation of conjugation chemistries, proof-of-concept scale to multi-gram manufacturing, and stability protocols. Supports random lysine, interchain cysteine, and enzymatic/size click-chemistry conjugation mechanisms.

macrocyclics.com
5Analytical Testing Services
TypeProfessional Services
Description

Standalone analytical services including HPLC qualification, HRMS-based Chelate Antibody Ratio analysis, impurity identification, and stability programs. Can be initiated as independent services or as part of cGMP development projects.

macrocyclics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Catalog chelating agents with unit pricing varying by product and quantity
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Product pricing ranges widely by compound. Examples: DOTAM-mono-acid (B-170) $116–$2,429; p-SCN-Bn-DOTA (B-205) $380–$4,639; DOTA-tris(t-Bu ester) (B-260) $308–$3,660; Lu-DOTA (M-144) $231–$924. Sizes typically available from 50 mg to 10 g or more. Products are manufactured to order except catalog in-stock items.

macrocyclics.com
2Custom GMP products quoted upon request
ModelOtherBilling cadenceMulti-year contract
Notes

GMP products are made to order, quoted upon request, and cannot be purchased online. Official quotations issued within 2 weeks. 10-week minimum lead time for manufacturing, drying, testing, and product release. Advanced planning required due to complexity of quality requirements and documentation.

macrocyclics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Macropa™
Description

A proprietary chelator compound sublicensed by Macrocyclics for Ac-225 radiopharmaceutical applications.

macrocyclics.com
Core offering1 text field

Macrocyclics designs, synthesizes, and manufactures macrocyclic chelating agents and cGMP-grade APIs that bind radioactive and lanthanide metal ions for radiopharmaceuticals, targeted alpha therapy, and MRI contrast agents. It sells a 100+ SKU catalog of bifunctional chelators, conjugates, macrocyclic ligands, MR reagents, reactive intermediates, fluorescent probes, and the Macropa™ Ac-225 platform, while providing integrated custom synthesis, bioconjugation, analytical testing, and cGMP manufacturing services for clinical-stage nuclear medicine programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 10-week minimum lead time for GMP production including manufacturing, drying, testing, and product release
+2 more records
Product overview1 text field

Macrocyclics is a CDMO specializing in chelating agents for radiopharmaceuticals and nuclear medicine. The product portfolio includes seven core product categories: Bifunctional Chelators (BFCs) with functionalized DOTA, DTPA, NOTA derivatives for targeting vector conjugation; Conjugates including DOTATATE and biotinylated compounds; Macrocyclic Ligands such as DOTA, NOTA, PCTA, and proprietary Macropa; Magnetic Resonance Reagents with pre-formed lanthanide complexes; Reactive Intermediates for custom synthesis; Fluorescent Probes for optical imaging; and the licensed Macropa™ platform for Ac-225 alpha therapy. The company also offers four service modules: cGMP manufacturing under ICH Q7/21 CFR 210&211, Custom Organic Synthesis, Bioconjugation, and Analytical Testing. Products are distributed from Plano, Texas with capabilities from multi-milligram research to kilogram-scale GMP production.

Product and service1 record
1Bifunctional Chelators (BFCs)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-06-13
Description

Macrocyclics acquired exclusive manufacturing and distribution rights for the Macropa™ chelator platform from Ratio Therapeutics in June 2025. Under the sublicense, Macrocyclics holds exclusive rights to manufacture, market, and commercially distribute Macropa as a standalone CDMO. Field-of-use restrictions prohibit use in PSMA or SSTR2 diagnostic/therapeutic applications without separate authorization from Ratio. Volume limitations apply: only up to 10mg vials per purchase order unless the customer has a separate license with Ratio.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

World's largest pure-play radiopharmaceutical manufacturer producing diagnostic and therapeutic radiopharmaceuticals at commercial scale. Comparable as a downstream customer/partner for chelators, but operates at finished-drug scale rather than the CDMO chelator niche where Macrocyclics sits.

TypeDirect peer
Description

German manufacturer of chelating agents (NOTA, DOTA, DTPA derivatives) and radiopharmaceutical precursors. Directly competes with Macrocyclics in supplying bifunctional chelators and custom radiolabeling precursors to pharma and academic researchers.

TypeBroad incumbent
Description

Swiss peptide CDMO with growing radioligand and oligonucleotide offerings. Comparable as a specialty CDMO supplying components to radiopharmaceutical developers, with GMP manufacturing scale well beyond Macrocyclics.

TypeBroad incumbent
Description

Major supplier of PET radiopharmaceuticals, MRI contrast agents, and molecular imaging consumables. Comparable as a broad incumbent in the radiopharmaceutical and contrast-agent space where Macrocyclics supplies enabling chemistry.

TypeRegional player
Description

South African state-linked producer and distributor of medical radioisotopes (Mo-99, I-131, Lu-177) and radiopharmaceuticals. Comparable as a vertically integrated radiopharma supplier, though primarily serving African and select international markets rather than the US CDMO niche Macrocyclics occupies.

TypeEmerging player
Description

German radiopharmaceutical group focused on therapeutic and diagnostic radioisotopes (Lu-177, Ac-225) and radioligand therapies. Comparable as an emerging player in the targeted radionuclide therapy space where Macrocyclics' Macropa for Ac-225 is positioned to supply.

TypeBroad incumbent
Description

Largest global CDMO network offering small-molecule API manufacturing, peptide synthesis, and radiopharmaceutical services through its Patheon/Cambrex franchises. Competes with Macrocyclics on GMP API manufacturing and custom synthesis, but as part of a much broader portfolio.

TypeBroad incumbent
Description

Global CDMO with peptide and radioligand manufacturing capabilities serving radiopharmaceutical developers. Comparable as a CDMO serving radiopharma customers, but operates at significantly larger scale and broader modality scope than Macrocyclics.

TypeDirect peer
Description

US-based radiopharmaceutical CDMO providing custom radiosynthesis, cold kits, and contract manufacturing for nuclear medicine developers. Comparable as a specialized radiopharma CDMO serving pharma and academic customers, though Macrocyclics is more chelator-focused.

10Chematech
TypeDirect peer
Description

French specialty chemical manufacturer focused on polyazamacrocyclic ligands and chelating agents for nuclear medicine and radiopharmaceutical applications. Closely comparable to Macrocyclics in macrocyclic ligand chemistry and catalog offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Macrocyclics

Radiopharmaceutical Contract Manufacturingmacrocyclics.com

Macrocyclics is a Plano, Texas-based CDMO that designs and manufactures macrocyclic chelating agents and cGMP APIs for radiopharmaceutical and nuclear medicine developers worldwide. It serves pharma, biotech, and academic research customers through catalog sales, custom synthesis, bioconjugation, and clinical-stage GMP manufacturing.

What Macrocyclics does

Macrocyclics is a Plano, Texas-based contract development and manufacturing organization (CDMO) that designs, synthesizes, and supplies macrocyclic chelating agents used to bind radioactive metal ions for radiopharmaceuticals, MRI contrast agents, and nuclear medicine research applications. Founded in 1995 by Professor A. Dean Sherry as a successor to Magnetic Resonance Solutions (1993), the company operates from a 20,000-square-foot facility equipped with two modular cGMP manufacturing suites, kilo-scale production equipment, and labs licensed for radionuclides used in PET imaging and therapeutic applications. Its core technology is macrocyclic chelation chemistry, with proprietary expertise spanning bifunctional chelators (DOTA, DTPA, NOTA, DOTAGA derivatives), macrocyclic ligands, pre-formed lanthanide complexes (e.g., Lu-DOTA, Gd-DOTA), and the Macropa™ platform for Ac-225 targeted alpha therapy, which is held under exclusive sublicense from Ratio Therapeutics.

The company's revenue model combines a transactional e-commerce catalog of more than 100 chelating agents and related reagents with project-based custom synthesis, bioconjugation, analytical testing, and cGMP manufacturing services quoted directly to enterprise customers. Pricing on catalog items ranges from roughly $62 to over $8,500 per unit, while custom and GMP work is quoted on multi-week lead times (a 10-week minimum for GMP production, with quotations issued within two weeks). Primary customers are pharmaceutical and biotechnology developers of radiopharmaceuticals and nuclear medicine programs, with a secondary segment of academic and molecular imaging research institutions. Marketing is heavily concentrated in industry conferences (SNMMI, WMIC, TRP Summit, ACS) and scientific publications.

Macrocyclics operates as a wholly-owned subsidiary of Orano Med, itself part of French nuclear conglomerate Orano Group, following an October 2011 acquisition that originated from an earlier cGMP contract for Orano Med's Pb-212 clinical program. The relationship with Orano Med underpins capital expansion: the company doubled its footprint in 2019 (Phase II) and completed a further Phase III expansion in June 2025, concurrent with acquiring exclusive Macropa™ commercial rights. Leadership rests with a small, PhD-heavy operations team including CEO Paul Jurek, Senior Chemist Eric Anderson, Production Lead Federico Rojas, and Manager of Business Development Duke Halloran.

Macrocyclics firmographics

Firmographics
Name
Macrocyclics
Legal name
Macrocyclics, Inc.
Website
https://macrocyclics.com
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
11–50 employees
Short description
Macrocyclics is a Plano, Texas-based CDMO that designs and manufactures macrocyclic chelating agents and cGMP APIs for radiopharmaceutical and nuclear medicine developers worldwide. It serves pharma, biotech, and academic research customers through catalog sales, custom synthesis, bioconjugation, and clinical-stage GMP manufacturing.
Ownership category
akta.pro rank

Macrocyclics industry classification

Industry
Product category
Radiopharmaceutical Contract Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860)
akta.pro industry
PRIMARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Macrocyclic chelating agents
  • Radiopharmaceutical manufacturing
  • CGMP API production
  • Bifunctional chelators
  • MRI contrast chemistry

Where Macrocyclics is headquartered

Location

Headquarters

HQ city
Plano
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Macrocyclics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Catalog Product Sales: Sale of catalog chelating agents and related compounds through an e-commerce platform. Products include Bifunctional Chelators (BFCs), Macrocyclic Ligands, Magnetic Resonance Reagents, Reactive Intermediates, Fluorescent Probes, Conjugates, and Macropa for Ac-225. Pricing ranges from $62 to over $8,500 per unit depending on product and quantity.
  2. cGMP Manufacturing for Clinical Trials: Custom GMP production of chelating agents, labeling precursors, and small molecule APIs for clinical investigation. Includes feasibility studies, engineering runs, GMP manufacturing, and final project reports with Statement of Work, raw materials data package, and Certificates of Analysis. 10-week minimum lead time; quoted upon request.
  3. Custom Organic Synthesis: Custom synthesis of new linker mechanisms, drug conjugates, imaging precursors, and complex intermediates at scales from multi-milligram to multi-gram and kilogram. Services include modification to chelator/linker, small molecule conjugates, and PET tracer precursors.
  4. Bioconjugation Services: Pre-clinical conjugation services for clinical trials, including evaluation of conjugation chemistries, proof-of-concept scale to multi-gram manufacturing, and stability protocols. Supports random lysine, interchain cysteine, and enzymatic/size click-chemistry conjugation mechanisms.
  5. Analytical Testing Services: Standalone analytical services including HPLC qualification, HRMS-based Chelate Antibody Ratio analysis, impurity identification, and stability programs. Can be initiated as independent services or as part of cGMP development projects.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCatalog chelating agents with unit pricing varying by product and quantity
OtherMulti-year contractCustom GMP products quoted upon request

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Macrocyclics product offering

Product offering

Core offering

Macrocyclics designs, synthesizes, and manufactures macrocyclic chelating agents and cGMP-grade APIs that bind radioactive and lanthanide metal ions for radiopharmaceuticals, targeted alpha therapy, and MRI contrast agents. It sells a 100+ SKU catalog of bifunctional chelators, conjugates, macrocyclic ligands, MR reagents, reactive intermediates, fluorescent probes, and the Macropa™ Ac-225 platform, while providing integrated custom synthesis, bioconjugation, analytical testing, and cGMP manufacturing services for clinical-stage nuclear medicine programs.

Product overview

Macrocyclics is a CDMO specializing in chelating agents for radiopharmaceuticals and nuclear medicine. The product portfolio includes seven core product categories: Bifunctional Chelators (BFCs) with functionalized DOTA, DTPA, NOTA derivatives for targeting vector conjugation; Conjugates including DOTATATE and biotinylated compounds; Macrocyclic Ligands such as DOTA, NOTA, PCTA, and proprietary Macropa; Magnetic Resonance Reagents with pre-formed lanthanide complexes; Reactive Intermediates for custom synthesis; Fluorescent Probes for optical imaging; and the licensed Macropa™ platform for Ac-225 alpha therapy. The company also offers four service modules: cGMP manufacturing under ICH Q7/21 CFR 210&211, Custom Organic Synthesis, Bioconjugation, and Analytical Testing. Products are distributed from Plano, Texas with capabilities from multi-milligram research to kilogram-scale GMP production.

Differentiator

Problem solved

Functional benefit

Brands

  • Macropa™: A proprietary chelator compound sublicensed by Macrocyclics for Ac-225 radiopharmaceutical applications.

Products and services

  • Bifunctional Chelators (BFCs)

Quantifiable outcome

  • 10-week minimum lead time for GMP production including manufacturing, drying, testing, and product release
  • +2 more outcomes

Companies that use Macrocyclics

Customer profile

Segments2 records

Ideal customer profiles2 records

Macrocyclics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Macrocyclics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ratio Therapeutics, Inc.coreOEM/ Whitelabel/ Licensing Partner · 13 June 2025Macrocyclics acquired exclusive manufacturing and distribution rights for the Macropa™ chelator platform from Ratio Therapeutics in June 2025. Under the sublicense, Macrocyclics holds exclusive rights to manufacture, market, and commercially distribute Macropa as a standalone CDMO. Field-of-use restrictions prohibit use in PSMA or SSTR2 diagnostic/therapeutic applications without separate authorization from Ratio. Volume limitations apply: only up to 10mg vials per purchase order unless the customer has a separate license with Ratio.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Macrocyclics competitors and assessment

Company assessment

Broad incumbents

  • Curium Pharma: World's largest pure-play radiopharmaceutical manufacturer producing diagnostic and therapeutic radiopharmaceuticals at commercial scale. Comparable as a downstream customer/partner for chelators, but operates at finished-drug scale rather than the CDMO chelator niche where Macrocyclics sits.
  • Bachem: Swiss peptide CDMO with growing radioligand and oligonucleotide offerings. Comparable as a specialty CDMO supplying components to radiopharmaceutical developers, with GMP manufacturing scale well beyond Macrocyclics.
  • GE HealthCare: Major supplier of PET radiopharmaceuticals, MRI contrast agents, and molecular imaging consumables. Comparable as a broad incumbent in the radiopharmaceutical and contrast-agent space where Macrocyclics supplies enabling chemistry.
  • Thermo Fisher Scientific (Patheon / Cambrex): Largest global CDMO network offering small-molecule API manufacturing, peptide synthesis, and radiopharmaceutical services through its Patheon/Cambrex franchises. Competes with Macrocyclics on GMP API manufacturing and custom synthesis, but as part of a much broader portfolio.
  • CordenPharma: Global CDMO with peptide and radioligand manufacturing capabilities serving radiopharmaceutical developers. Comparable as a CDMO serving radiopharma customers, but operates at significantly larger scale and broader modality scope than Macrocyclics.

Direct peers

  • ABX Advanced Biochemical Compounds: German manufacturer of chelating agents (NOTA, DOTA, DTPA derivatives) and radiopharmaceutical precursors. Directly competes with Macrocyclics in supplying bifunctional chelators and custom radiolabeling precursors to pharma and academic researchers.
  • IsoTherapeutics: US-based radiopharmaceutical CDMO providing custom radiosynthesis, cold kits, and contract manufacturing for nuclear medicine developers. Comparable as a specialized radiopharma CDMO serving pharma and academic customers, though Macrocyclics is more chelator-focused.
  • Chematech: French specialty chemical manufacturer focused on polyazamacrocyclic ligands and chelating agents for nuclear medicine and radiopharmaceutical applications. Closely comparable to Macrocyclics in macrocyclic ligand chemistry and catalog offerings.

Regional players

  • NTP Radioisotopes: South African state-linked producer and distributor of medical radioisotopes (Mo-99, I-131, Lu-177) and radiopharmaceuticals. Comparable as a vertically integrated radiopharma supplier, though primarily serving African and select international markets rather than the US CDMO niche Macrocyclics occupies.

Emerging players

  • ITM (Isotope Technologies Munich): German radiopharmaceutical group focused on therapeutic and diagnostic radioisotopes (Lu-177, Ac-225) and radioligand therapies. Comparable as an emerging player in the targeted radionuclide therapy space where Macrocyclics' Macropa for Ac-225 is positioned to supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Macrocyclics social profiles

Digital presence

Macrocyclics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Macrocyclics leadership team

Management profile

Number of profiles

Profiles4 records

Macrocyclics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Macrocyclics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Macrocyclics

What does Macrocyclics do?

Macrocyclics designs, synthesizes, and manufactures macrocyclic chelating agents and cGMP-grade APIs that bind radioactive and lanthanide metal ions for radiopharmaceuticals, targeted alpha therapy, and MRI contrast agents. It sells a 100+ SKU catalog of bifunctional chelators, conjugates, macrocyclic ligands, MR reagents, reactive intermediates, fluorescent probes, and the Macropa™ Ac-225 platform, while providing integrated custom synthesis, bioconjugation, analytical testing, and cGMP manufacturing services for clinical-stage nuclear medicine programs.

Is Macrocyclics a public or private company?

Macrocyclics is a private company. It is classified as corporate owned and is currently operating.

When was Macrocyclics founded?

Macrocyclics was founded in 1995. It employs 11 to 50 people.

Where is Macrocyclics based?

Macrocyclics is headquartered in Plano, United States, in the North America region.

How does Macrocyclics make money?

Five revenue lines are on record. Catalog Product Sales are the primary driver. The others are cGMP Manufacturing for Clinical Trials, custom Organic Synthesis, bioconjugation Services and analytical Testing Services.

Who are Macrocyclics's main competitors?

Broad incumbents on record are Curium Pharma, Bachem, GE HealthCare, Thermo Fisher Scientific (Patheon / Cambrex) and CordenPharma. Direct peers are ABX Advanced Biochemical Compounds, IsoTherapeutics and Chematech. NTP Radioisotopes is listed as a regional player. ITM (Isotope Technologies Munich) is listed as an emerging player.

Does Macrocyclics have an API?

No public API is recorded for Macrocyclics.

What industry is Macrocyclics in?

Macrocyclics's product category is Radiopharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services, with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals